These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 31591209)

  • 1. DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
    Abbotts R; Topper MJ; Biondi C; Fontaine D; Goswami R; Stojanovic L; Choi EY; McLaughlin L; Kogan AA; Xia L; Lapidus R; Mahmood J; Baylin SB; Rassool FV
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22609-22618. PubMed ID: 31591209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency.
    McLaughlin LJ; Stojanovic L; Kogan AA; Rutherford JL; Choi EY; Yen RC; Xia L; Zou Y; Lapidus RG; Baylin SB; Topper MJ; Rassool FV
    Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17785-17795. PubMed ID: 32651270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
    Ji W; Weng X; Xu D; Cai S; Lou H; Ding L
    Biochem Biophys Res Commun; 2020 Jan; 522(1):121-126. PubMed ID: 31753490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
    Heerma van Voss MR; Brilliant JD; Vesuna F; Bol GM; van der Wall E; van Diest PJ; Raman V
    Med Oncol; 2017 Mar; 34(3):33. PubMed ID: 28138868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining and Modulating 'BRCAness'.
    Byrum AK; Vindigni A; Mosammaparast N
    Trends Cell Biol; 2019 Sep; 29(9):740-751. PubMed ID: 31362850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
    Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
    Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Small Compound KJ-28d Enhances the Sensitivity of Non-Small Cell Lung Cancer to Radio- and Chemotherapy.
    Ryu H; Kim HJ; Song JY; Hwang SG; Kim JS; Kim J; Bui THN; Choi HK; Ahn J
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation.
    Wilson A; Menon V; Khan Z; Alam A; Litovchick L; Yakovlev V
    Redox Biol; 2019 Jun; 24():101169. PubMed ID: 30889466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells.
    Guo ZP; Hu YC; Xie Y; Jin F; Song ZQ; Liu XD; Ma T; Zhou PK
    Biochem Biophys Res Commun; 2017 Jan; 483(1):223-229. PubMed ID: 28034751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
    Gaziev AI
    Radiats Biol Radioecol; 2014; 54(3):229-40. PubMed ID: 25764827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
    Kristeleit RS; Miller RE; Kohn EC
    Am Soc Clin Oncol Educ Book; 2016; 35():e259-68. PubMed ID: 27249731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
    Zatreanu D; Robinson HMR; Alkhatib O; Boursier M; Finch H; Geo L; Grande D; Grinkevich V; Heald RA; Langdon S; Majithiya J; McWhirter C; Martin NMB; Moore S; Neves J; Rajendra E; Ranzani M; Schaedler T; Stockley M; Wiggins K; Brough R; Sridhar S; Gulati A; Shao N; Badder LM; Novo D; Knight EG; Marlow R; Haider S; Callen E; Hewitt G; Schimmel J; Prevo R; Alli C; Ferdinand A; Bell C; Blencowe P; Bot C; Calder M; Charles M; Curry J; Ekwuru T; Ewings K; Krajewski W; MacDonald E; McCarron H; Pang L; Pedder C; Rigoreau L; Swarbrick M; Wheatley E; Willis S; Wong AC; Nussenzweig A; Tijsterman M; Tutt A; Boulton SJ; Higgins GS; Pettitt SJ; Smith GCM; Lord CJ
    Nat Commun; 2021 Jun; 12(1):3636. PubMed ID: 34140467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
    Lee JM; Ledermann JA; Kohn EC
    Ann Oncol; 2014 Jan; 25(1):32-40. PubMed ID: 24225019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
    Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
    J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.